Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With four funds, the firm has more than $200 million under management.

The first fund, HVP I, is a $3M fund focused on pre-seed and company formation. The second fund, HVP II, is a $35M investment in HBM BioCapital, through which Hatteras is an investment advisor. HVP III is an $83M early-stage fund that invests in breakthrough discoveries that impact human medicine. With a strategy similar to HVP III, in August 2011 the firm launched HVP IV with $74 million in subscriptions toward a final fund target of $125 million. With HVP IV, Hatteras has formally launched "Hatteras Discovery", an allocation of the fund focused on seed-stage companies and projects in the field of human medicine and life sciences.

Core to the mission of Hatteras Venture Partners is a belief that entrepreneurial innovation will create valuable new products that will transform the practice of medicine and create value for our investors. As entrepreneurs, operators, and investors, we are dedicated to the success of our companies and to the men and women who create them.

Hatteras is an Innovation to Impact sponsor of the Council for Entrepreneurial Development, a member of NCBIO, and an active volunteer in support of North Carolina and Southeast regional biotech activities.